Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jad Chahoud"'
Autor:
Lucas Campedel, Laure Hirsch, Toni K. Choueiri, Praful Ravi, Dylan J. Martini, Omar Alhalabi, Elshad Hasanov, Ziad Bakouny, Nizar M. Tannir, Jonathan Thouvenin, Srinivas R. Viswanathan, Mehmet Asim Bilen, Philippe Barthélémy, Delphine Borchiellini, Karim Amrane, Gabriel G. Malouf, Jad Chahoud
Publikováno v:
Journal of Clinical Oncology. 39:274-274
274 Background: MiT family translocation renal cell carcinomas (TRCC) represent a rare and aggressive subgroup of RCC harboring high expression of c-MET. While response rates of VEGF receptor-tyrosine kinase inhibitor and immune checkpoint inhibitors
Autor:
Amishi Yogesh Shah, A. Zurita Saavedra, Eric Jonasch, Jad Chahoud, Andrew James Wiele, Nizar M. Tannir, Lianchun Xiao, Jeremy A. Ross, Zita Dubauskas Lim, Matthew T. Campbell
Publikováno v:
Annals of Oncology. 30:v390
Background ICI and VEGFR-targeted therapies are the primary treatments for mRCC. Len plus Eve is currently approved based on improved progression-free survival (PFS) in pts with progressive disease after one prior VEGFR-targeted therapy. However, its
Autor:
Srdan Verstovsek, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Jad Chahoud, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Sherry Pierce, Musa Yilmaz, Guillermo Garcia-Manero, William G. Wierda, Nitin Jain, Koji Sasaki
Publikováno v:
Blood. 126:3722-3722
Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month